Chronic Migraine Epidemiology and Disease Burden

Authors: Aubrey N Manack Dawn C Buse Richard B Lipton

Publish Date: 2010/11/10

Volume: 15, Issue: 1, Pages: 70-78

PDF Link

Abstract

Chronic migraine is a common and disabling complication of migraine with a population prevalence of about 2 Emerging evidence suggests that episodic migraine and chronic migraine differ not only in degree but also in kind Compared with patients with episodic migraine those with chronic migraine have worse socioeconomic status reduced healthrelated quality of life increased headacherelated burden including impairment in occupational social and family functioning and greater psychiatric and medical comorbidities Each year approximately 25 of patients with episodic migraine develop newonset chronic migraine ie chronification Understanding the natural disease course improving treatment and management and preventing the onset could reduce the enormous individual and societal burden of chronic migraine and thus have become important goals of headache research This review provides a summary of the history of nomenclature and diagnostic criteria as well as recent studies focusing on the epidemiology natural history and burden of chronic migraineDr Aubrey N Manack is a fulltime employee of Allergan Inc Dr Dawn C Buse has served as a consultant to Allergan and has received grants or has grants pending with Allergan Merck Pharmaceuticals Endo Pharmaceuticals OrthoMcNeil Pharmaceuticals and GlaxoSmithKline Dr Richard B Lipton is a member of the advisory boards of Allergan Merck and MAP Pharmaceuticals Inc has served as a consultant for Allergan has received grants or has grants pending with Allergan Merck Pharmaceuticals GlaxoSmithKline and BristolMyers Squibb has received payment for manuscript preparation from Allergan has received payment for the development of educational presentations from Allergan and has received travel expense compensation from Allergan and Merck

Keywords: